Thursday, May 23, 2019
engineered enzymes for better healthcare


Tyrosinaemia Type I (TYR-I) is caused by the absence of an enzyme participating in the metabolism of amino acid tyrosine and occurs in approximately 1 in every 80,000 newborns. The by-products of tyrosine metabolism, particularly a very toxic compound called succinylacetone, build up in the liver. Symptoms generally begin in the first few weeks of life and progress to liver or kidney failure, nerve damage and death. Drug treatment along with a low-protein diet is very effective in preventing liver and kidney damage.

Product Info


amino-acid-disorders-productDisorders of Amino Acid Metabolism

PKU        Phenylketonuria

MSUD     Maple Syrup Urine Disease

HCY        Homocystinuria

TYR-I      Tyrosinaemia Type-I


Language Selection


Latest News

Newborn Screening - First Steps into the marketplace
Irish technology to enable metabolic disorder screening among newborns in the developing world and remote locations... Read full article on the web Technology…


Screen your baby’s health
Enzolve Technologies recently launched a novel newborn screening test for Phenylketonuria (PKU), an inherited metabolic disorder that results in severe mental…


UCD campus company to begin production of newborn screening kits for international markets
Enzolve Technologies has recently secured substantial investment from Enterprise Ireland to allow them to begin immediate production of diagnostic screening kits…